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We demonstrated that exogenous pyruvate promotes survival under glucose depletion in aerobic mutant
p53 (R175H) human melanoma cells. Others subsequently indicated that mutant p53 tumor cells
undergo p53 degradation and cell death under aerobic glucose-free conditions. Since glucose starvation
occurs in hypoxic gradients of poorly vascularized tumors, we investigated the role of p53 siRNA under
hypoxia in wt p53 C8161 melanoma using glucose starvation or 5 mM physiological glucose. p53 Silenc-
ing decreased survival of glucose-starved C8161 melanoma with pyruvate supplementation under
hypoxia (61% oxygen), but increased resistance to glycolytic inhibitors oxamate and 2-deoxyglucose in
5 mM glucose, preferentially under normoxia. Aiming to counteract hypoxic tumor cell survival irrespec-
tive of p53 status, genetically-matched human C8161 melanoma harboring wt p53 or mutant p53
(R175H) were used combining true hypoxia (61% oxygen) and hypoxia mimetic CoCl2. No signiﬁcant
decrease in metabolic activity was evidenced in C8161 melanoma irrespective of p53 status in 2.5 mM
glucose after 48 h of physical hypoxia. However, combining the latter with 100 lM CoCl2 was preferen-
tially toxic for mutant p53 C8161 melanoma, and was enhanced by catalase in wt p53 C8161 cells. Down-
regulation of MnSOD and LDHA accompanied the toxicity induced by hypoxia and CoCl2 in 5 mM glucose,
and these changes were enhanced by oxamate or 2-deoxyglucose. Our results show for the ﬁrst time that
survival of malignant cells in a hypoxic microenvironment can be counteracted by hypoxia mimetic
co-treatment in a p53 dependent manner.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction hypoxic environment induces a high rate of glycolysis promotingEvolving solid tumors become progressively distant from vascu-
larized regions, being exposed to a restrictive microenvironment
characterized by sub-optimal levels of oxygen and glucose. This re-
quires induction of the hypoxia inducible factor (HIF-1a) to facili-
tate adaptative survival in response to these metabolic stresses
[1,2]. Transient activation of HIF-1amay be protective under phys-
iological conditions in response to stress. However, prolonged and
severe hypoxia can lead to oxidative stress and cytotoxicity [3]. To
counteract the scarce glucose in poorly vascularized tumors, theaddiction to glucose [4–8]. During the shift from mitochondrial
oxidative phosphorylation towards glycolysis, HIF-1a favours
induction of lactate dehydrogenase A (LDHA) which regulates the
conversion of pyruvate to lactate, a hallmark of glycolysis [9,10].
A consequence of tumor cell adaptation to low oxygen and
sub-physiological glucose is lower efﬁcacy of cancer therapy, since
survival under severe hypoxia may select for mutant cells with
decreased response to some cancer treatments [3,11,12]. Tolerance
to oxygen restriction also contributes to tumor cell survival by
helping to down-regulate expression of key pro-apoptotic genes
like Bid and Bax [13]. Although cells with wild type p53 are more
likely to undergo apoptosis, cell cycle arrest or senescence in re-
sponse to DNA damage, their response may be hampered in hypox-
ia [14–16]. Using genetically-matched human C8161 melanoma
with wt p53 or mutant p53 (R175H), our laboratory showed that
overnight glucose depletion caused cell death irrespective of p53
status counteracted by N-acetylcysteine [17]. However, glucose
depletion preferentially permitted survival of mutant p53 cells
with pyruvate supplementation [17]. Others reported more
recently that mutant p53 breast cancer cell lines MDA-231,
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lation and autophagic degradation of mutant p53 protein and cell
death, effect not seen in unmatched wt p53 cells [18]. Both of
the latter reports used cells under aerobic conditions [17,18]
underscoring that glucose depletion and high metabolic demand
leads to tumor cell death, because of unfulﬁlled glucose addiction
[7]. Cancer cells are frequently maintained in vitro in complete
medium containing 10% serum and 20 mM glucose, which is about
4-fold higher than the physiological glucose levels [17,18]. How-
ever, the response to glucose restriction is more likely to occur un-
der hypoxia, which is experimentally induced using either hypoxia
mimetics like CoCl2 or by true hypoxia (61% oxygen) [19,20]. To
learn about the role of p53 under glucose starvation or 5 mM glu-
cose, we ﬁrst used p53siRNA and scrambled siRNA sequences in
parental wt p53 C8161 melanoma. Since the consequences of gene
silencing are not identical to those involving p53 mutation, we also
investigated the glucose dependent responses in genetically-
matched human C8161 melanoma harboring wt p53 or mutant
p53 (R175H) [17], attempting to learn whether hypoxia and CoCl2
cooperate to enhance tumor cell death in physiological 5 mM glu-
cose or lower glucose.2. Materials and methods
2.1. Cell lines
(a) Parental human C8161 melanoma harboring wt p53 [21]. (b)
Human C8161 melanoma harboring wt or mutant p53 status – iso-
genic C8161 melanoma were obtained by retroviral transduction of
parental wt p53 C8161 cells. We used calcium chloride transfec-
tion of Phoenix cells with pWZL-Hygro plasmid harboring a human
p53 arginine-175 histidine mut gene, which is a dominant-
negative mutant p53 plasmid [17]. Control cells were retrovirally
transduced with the empty pWZL-Hygro plasmid. Both plasmids
were kindly provided by Dr. Scott Lowe, Cold Spring Harbor Labo-
ratory, Cold Spring Harbor, New York. Veriﬁcation of p53 status
was achieved by immune precipitation of mutant p53 with mono-
clonal antibody Pab 240 (SC-99) which is mutant p53-speciﬁc un-
der non denaturing conditions; wt p53 was identiﬁed by its lack of
immune precipitation with Pab 240 (SC-99) under non denaturing
immune precipitation and reactivity with monoclonal antibody
(Pab DO-1-SC-126) under comparable conditions. Immune precip-
itated proteins were subjected to SDS–PAGE, bi directionally
blotted onto nitrocellulose membranes and p53 identiﬁed by the
DO-1 (SC126) monoclonal antibody, which recognizes both wt
and mutant p53 in denatured form. Both antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Santa
Cruz, CA).2.2. Glucose and serum starvation
Experiments involving glucose depletion were carried out by
seeding the cells overnight in a complete medium consisting of
Dulbecco’s ModiﬁedMedium (DME) Sigma Cat # D1152 containing
4.5 g/lL glucose (23 mM) supplemented with 4 mM glutamine
and 10% fetal calf serum. After allowing 20 h for cell attachment,
adherent cells were extensively washed 3 times in isotonic phos-
phate-buffered saline pH 7.3, followed by addition of Dulbecco’s
Modiﬁed Eagle’s Medium Sigma Cat # D5030, supplemented with
4 mM glutamine and bicarbonate without glucose or sodium
pyruvate. Glucose and fetal calf serum concentrations were added
to the glucose-free D5030 medium, as indicated in each experi-
ment and physiological glucose was estimated around 5 mM levels
[22].2.3. Hypoxia
Cells were incubated for different times (24 or 48 h) in low oxy-
gen (61% O2) in hypoxic C-474 chamber equipped with Pro-Ox 110
oxygen controlling regulators (Biospherix) which provided (61%).
Whenever indicated, CoCl2 was added during cell seeding prior
to subjecting the cells to low oxygen or normoxia.
2.4. Transient p53 siRNA silencing
This was carried out using the Invitrogen Neon electroporation
system (Cat No. MPK5000) containing 5  106 cells resuspended in
100 ll buffer R (Cat No. MPK10025R) and 4 ll containing 10 nM
of p53 siRNA (H) duplex standardized to silence p53 (Cat #
SC-29435). Cells were treated in parallel with a comparable con-
centration of negative control siRNA-A (Cat # SC-36868), a non-
targeting duplex of the same length as the speciﬁc p53 siRNA. Both
siRNA types were obtained from Santa Cruz Biotechnology. Cells
were subjected to electroporation using 2 pulses (width 30 and
1150 voltage) and subsequently seeded to 35% conﬂuence in med-
ium devoid of antibiotics in 96 well plates. After 12 h, cultures
were washed and subjected to the treatments in glucose-free
medium with glucose supplementation as indicated, for further
assays within 48 h.
2.5. Relative toxicity/metabolic activity and live–dead assays
(a) Toxicity/metabolic activity was estimated with Alamar Blue
(resazurin)whichmeasures intracellular redoxmitochondrial activ-
ity by quantitating the cell-catalyzed conversion of non-ﬂuorescent
resazurin to ﬂuorescent resoruﬁn [23]. Alamar Blue was added to a
10% ﬁnal concentration to each one of 96 well plates after the
appropriate treatment, the dye is non-toxic, allows ﬂuorescent
quantitation, permits re-use for further investigation such as mor-
phological, biochemical and clonogenic analyses. As such, this assay
is valuable as an endpoint of proliferation or relative metabolic
activity, rather than a kinetic measure for monitoring cell growth.
For these experiments, cells (10,000) were allowed to adhere over-
night in 96 well TC microtiter dishes. After the corresponding treat-
ments, Alamar Blue (BioSource, Camarillo, CA, USA) was added
without removing medium containing dead cells, and ﬂuorescence
was measured 4 h later in a Fluoroskan Ascent microplate reader
with an excitation of 544 nm and an emission of 590 nm.
(b) Live–dead ratio was determined by adding Calcein AM and
propidium iodide directly to the cell cultures. Subsequently,
cytoﬂuorometry was used to determine the ratio of live cells with
(Calcein – green ﬂuorescence) and dead (propidium iodide – red
ﬂuorescence) in an Isocyte laser spectroﬂuorometer [22].
2.6. Apoptosis-associated PARP cleavage
This was investigated in cell lysates following SDS–PAGE and
immune blotting using an antibody PARP (SC-7150 from Santa
Cruz Biotechnology), followed by reaction with protein A conju-
gated to peroxidase and chemiluminescence. Subsequently, images
were digitalized and quantitated to deﬁne the ratio of cleaved to
intact PARP [17,19].
2.7. Statistical studies
One-Way Analysis of Variance (ANOVA) test was conducted
with SigmaPlot 11.0 (Systat Software, Inc, San Jose, CA, USA), to
determine whether there was a statistically signiﬁcant differences
evaluated versus the control groups. In each Figure, ⁄p 6 0.005,
showed a statistically signiﬁcant difference whenever indicated
[17].
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3.1. p53 siRNA decreases survival of pyruvate supplemented glucose-
depleted cells under hypoxia but promotes resistance to oxamate and
2-DG in 5 mM glucose
In parental wt p53 C8161 melanoma cells, p53 siRNA was intro-
duced at high efﬁciency by electroporation to silence wt p53
expression compared to that seen in the same cells in which
scrambled negative-control siRNA was similarly electroporated.
Within 3 days of electroporation, cells were assayed by plating
them in medium supplemented with the glucose concentrations
indicated in each case. Immune blotting conﬁrmed that p53 siRNA
decreased p53 protein expression when normalized to reference
actin levels (Fig. 1A). In hypoxic cells depleted of glucose and sup-
plemented with 5 mM pyruvate, p53 siRNA decreased the number
of viable cells, indicated by greater uptake of the cell impermeable
DNA-binding propidium iodide. Moreover, within the live cell pop-
ulation, those electroporated with p53 siRNA showed decreased
green ﬂuorescence following addition of Calcein AM (Fig. 1B). This
may be linked to lower live cell associated esterase activity in-
duced by p53 siRNA, an early event that precedes decreased cell
viability, as shown by others [22]. However, with 5 mM glucose
supplementation, p53 siRNA increased resistance to oxamate and
2-deoxyglucose preferentially under normoxia, although this effect
was decreased under hypoxia (Fig. 1C).3.2. Metabolic activity under physical hypoxia and PARP cleavage by
exposure to 2.5 mM glucose and 100 lM CoCl2 are preferentially
decreased in mut p53 C8161 cells
Genetically-matched C8161 melanoma harboring a wt p53 or
mutant p53 R175H cell were used. A mutation within one allele
of the p53 tumor suppressor gene can inactivate the remainingFig. 1. C8161 melanoma cells electroporated with p53 siRNA or negative control sequen
blotting; (B) % of live/dead cells following glucose depletion and pyruvate supplementati
oxamate, 3-bromopyruvate or 2-deoxyglucose under normoxia or hypoxia, measured by
of relative percentage of metabolic activity for each treatment group ± standard deviatiwild-type allele in a dominant-negative manner and in some cases
can exert additional activities, known as mutant p53 ‘gain of func-
tion’ [24]. Diminished function in cells transduced with mutant
p53 (R175H) was seen by an over-expressed dysfunctional p53
protein, since there was negligible expression of the p53-activated
p21WAF1 protein, compared to that in the corresponding wt p53
cells. [17]. When these matched cells were cultured for 48 h under
normoxia in either 2.5 or 10 mM glucose, those harboring mutant
p53 showed greater metabolic activity, even in the presence of
100 lM CoCl2 (Fig. 2, upper left). However, when these cells were
assayed in parallel following 48 h in 61% O2, metabolic activity of
cells with mutant p53 in 2.5 mM glucose was preferentially de-
creased in the presence of 100 lM CoCl2 (Fig. 2, lower left). We
also conﬁrmed that CoCl2 increases PARP cleavage counteracted
by NAC (N-acetylcysteine) in mutant p53 cells after 18 h in
1.25 mM glucose and 2% dialyzed serum. CoCl2 treatment in low
glucose increased AMPK phosphorylation (pAMPK) presumably
via oxidative stress since this was counteracted by NAC (Fig. 2,
right) [25].3.3. Catalase and 100 lM CoCl2 potentiate hypoxia-mediated cell
death in C8161 cells in a p53-regulated manner
Since wt p53 C8161 melanoma cells showed relatively greater
resistance to glucose starvation, cells were exposed to hypoxia
and/or CoCl2, in 5 mM glucose including glycolytic inhibitors like
oxamate or 2-deoxyglucose, and exogenous superoxide dismutase
or catalase whenever indicated. This revealed a lower survival of
wt p53 cells jointly treated with catalase, hypoxia and CoCl2. In
contrast, in 5 mM glucose, control and superoxide dismutase-trea-
ted mutant p53 C8161 melanoma retained viability, but this was
decreased in the presence of the glycolytic inhibitors when these
cells were treated with hypoxia and CoCl2, (Fig. 3).ces were assayed for: (A) changes in p53 expression normalized to actin by immune
on under hypoxia measured by laser-based 2 channel ﬂuorescence; (C) resistance to
Alamar Blue ﬂuorescence. The bars shown in (B) and (C) represent the median value
on (SD); n = 4.⁄P < 0.005 there was a statistically signiﬁcant difference [17].
Fig. 2. Cells seeded in complete medium overnight were washed to remove glucose. Subsequently glucose-free medium supplemented with 2.5 or 10 mM glucose and 5%
dialyzed serum including CoCl2 at the concentrations indicated was added to the cells which were maintained for 48 h in (A) normoxia or (B) hypoxia (61% oxygen). (C) CoCl2
increases PARP cleavage counteracted by NAC in mutant p53 C8161 cells (lower panel) after 18 h in 1.25 mM glucose, 2% dialyzed serum.
Fig. 3. Sparse cells were seeded in complete medium with CoCl2 for pre-conditioning whenever indicated for 48 h prior to changing to medium with 5 mM glucose, 5%
dialyzed serum with the additions of enzymes and glycolytic inhibitors and CoCl2 indicated in each case, followed by 48 h under hypoxia. (A) wt p53 C8161 cells; (B) mut p53
C8161 cells.
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Fig. 4. (A) wt p53 or mutant p53 C8161 cells were seeded in medium with 10% serum and 20 mM glucose including 100 lM CoCl2 for 12 h. All cultures were transferred to
hypoxia in medium with 5 mM glucose and 5% dialyzed serum by 12 h, followed by 6 h of re-oxygenation +/ CoCl2 and the additions indicated in each case for 12 h. (B) cells
were treated as above indicated +/ CoCl2 under normoxic conditions. In both cases, cells were harvested and analyzed by immune blotting [17].
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5 mM glucose
Since superoxide anion is induced by glucose starvation and
may enhance mitochondrial oxidative stress [26], we investigated
whether MnSOD, was unequally affected by hypoxia (61% oxygen)
in the absence or presence of CoCl2 in genetically-matched C8161
cells with differing p53 status exposed to 5 mM glucose. No signif-
icant difference in MnSOD expression related to p53 status was
seen under hypoxia, but joint treatment with hypoxia and CoCl2
essentially depleted MnSOD from both cell types. Since glycolytic
LDHA is also induced by hypoxia [9,10], its p53-associated modu-
lation by hypoxia ± CoCl2 was also studied. This revealed that
LDHA is increased in hypoxic mutant p53 cells compared to their
wt p53 counterparts. However, adding CoCl2 down-regulated
LDHA preferentially in mutant p53 cells, compared to its expres-
sion in the absence of CoCl2 (upper Fig. 4A). In contrast to the
greater LDHA expression under hypoxia in mutant p53 cells, no
p53-associated difference in LDHA expression was seen in C8161
melanoma when assayed under normoxia, irrespective of CoCl2
addition (lower Fig. 4A).4. Discussion
Previous reports have indicated that glucose depletion of mela-
noma [17] and carcinoma cells [18] promotes tumor cell death.
However, we showed that glucose depletion with pyruvate supple-
mentation preferentially permitted survival of mutant p53 cells
[17]. Both of these reports used cells under aerobic conditions[17,18]. Since glucose starvation occurs in hypoxic gradients of
poorly vascularized tumors, we now introduced p53 siRNA or mu-
tant p53R175H into human melanoma cells, to investigate how
they responded to glucose starvation or to physiological 5 mM
glucose under hypoxia or normoxia in the presence or absence of
glycolytic inhibitors. This revealed that p53 siRNA decreases sur-
vival of glucose-starved C8161 melanoma with pyruvate supple-
mentation under hypoxia. In 5 mM glucose, p53 siRNA rather
increased resistance to oxamate or 2-deoxyglucose particularly
under normoxia. These results suggested that diminishing wt
p53 by silencing decreases the ability of pyruvate to counteract
glucose starvation. Reciprocally, p53 siRNA silencing seems to con-
tribute to survival in 5 mM glucose (Fig. 1). In experimental sys-
tems, hypoxia is alternatively induced in a low oxygen chamber
or aerobically by hypoxia mimetics like CoCl2. When matched
C8161 melanoma with wt p53 or mutant p53 R175H are com-
pared, the latter becomemore susceptible in 2.5 mM glucose under
hypoxia (61% O2), particularly when the low oxygen treatment is
accompanied by the hypoxia mimetic CoCl2. This report is the ﬁrst
to show that hypoxia and CoCl2 cooperate to preferentially en-
hance loss of metabolic activity in mutant p53 C8161 melanoma
exposed to sub-physiological glucose, when compared to their iso-
genic wt p53 counterpart subjected to the same conditions (Fig. 2).
The cooperation between hypoxia and CoCl2 was also seen in 5 mM
glucose when C8161 melanoma cells were treated with glycolytic
inhibitors like oxamate or 2-deoxyglucose or when exogenous cat-
alase was added (Fig. 3). The catalase-mediated potentiation of
toxicity in cells jointly treated with hypoxia and CoCl2 may be re-
lated to results showing that epidermal growth factor up-regulates
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ishing this up-regulation in ovarian carcinoma cells [28]. C8161
melanoma cells responded to joint hypoxia and CoCl2 by down-
regulating signiﬁcantly MnSOD (SOD2) [29] and glycolytic LDHA
(Fig. 4). We hypothesize that lower MnSOD and LDHA jointly
induced by hypoxia and CoCl2 may augment the oxidative stress
produced by each treatment individually, leading to accumulation
of mitochondrial superoxide anion [26,27] and to lower glycolysis
[9,10]. It will be interesting to examine in other tumor cells
whether dual treatment with hypoxia and CoCl2 also down-regu-
late LDHA and SOD2 proteins, since these 2 proteins increase in
aggressive glycolytic pheochromocytomas and paragangliomas
[29]. Taken together, our results suggest that p53 inactivation by
silencing or mutation confers susceptibility to glucose starvation,
particularly under hypoxia. Our results also show that hypoxia and
hypoxia mimetics are not redundant, and may cooperate together
to counteract survival of aggressive cancer cell variants capable of
resisting the stress of hypoxic tumor microenvironments.
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